At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a Bcl-2 Antagonist, Plus Topotecan in Relapsed Small Cell Lung Carcinoma
In Brief
A Phase 2 clinical trial evaluating obatoclax mesylate, topotecan hydrochloride, and 1 other intervention for Recurrent Small Cell Lung Cancer and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan hydrochloride and to see how well they work in treating patients with relapsed or refractory small cell lung cancer or advanced solid tumors. Obatoclax mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving obatoclax mesylate together with topotecan hydrochloride may help kill more tumor cells
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies